RxDoctor Payments Data

Farah Salem, MD

Internal Medicine · Warren, MINPI 1093979593

Payments from drug & device makers

$2,272in general payments, 2019–2025

Across 65 payments — averaging $34.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$401
  • AstraZeneca$398
  • Novo Nordisk$371
  • Organogenesis Inc.$311
  • Amgen$144
  • Pfizer$129
  • plus $517 from 11 others

What the payments were for

  • Food & beverage$2,272100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,272 in reported general payments places this provider in the 80th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$107,167
Medicare patients
206
Services billed
1,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide103$107,289
OzempicSemaglutide66$79,071
JardianceEmpagliflozin84$74,400
EliquisApixaban58$60,265
JanuviaSitagliptin Phosphate56$55,264
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$51,413
RybelsusSemaglutide30$38,801
LinzessLinaclotide31$27,177
TrulicityDulaglutide17$22,371
XareltoRivaroxaban20$20,325
FarxigaDapagliflozin Propanediol28$19,644
Repatha SureclickEvolocumab16$13,821
Diclofenac Sodium43$9,666
Janumet XrSitagliptin Phos/Metformin Hcl12$8,775
Albuterol Sulfate HfaAlbuterol Sulfate86$4,283

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$401$129,660120 claims
Novo NordiskOzempic, Rybelsus$371$117,87296 claims
PfizerEliquis$129$60,26558 claims
GSKTrelegy Ellipta$116$51,41358 claims
AstraZenecaFarxiga$398$19,64428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Warren

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →